Greenwich LifeSciences

GLSI43

$14.50arrow_drop_up8.45%$1.13

GLSI43

$14.50

arrow_drop_up8.45%$1.13

Performance History

Key Stats
Open	$13.51
Prev. Close	$13.37
EPS	-0.79
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$190.59M
PE Ratio	-

	LOW	HIGH
Day Range	13.13	14.60
52 Week Range	7.58	21.44

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.79

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Greenwich LifeSciences (GLSI)

Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company focused on the development of a novel immunotherapy drug for the prevention of breast cancer recurrences in patients who have undergone surgery. The company's lead product candidate, GP2, is a peptide-based immunotherapy that targets HER2/neu, a protein that is overexpressed in about 75% of breast cancer patients. GP2 is designed to stimulate the immune system to recognize and kill breast cancer cells that express HER2/neu. This targeted approach has the potential to significantly improve patient outcomes by reducing the risk of cancer recurrence.

The company's development strategy for GP2 is based on promising clinical data from previous studies. In a Phase 2b clinical trial, GP2 demonstrated a 0% recurrence rate in high-risk HER2-positive breast cancer patients after a median follow-up of 5.4 years. These results are highly encouraging and suggest that GP2 could be an effective treatment option for preventing breast cancer recurrences. Greenwich LifeSciences plans to advance GP2 into a Phase 3 clinical trial, which is the final stage of testing before seeking regulatory approval.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Snehal S. Patel
Headquarters: Stafford
Employees: 3
Exchange: NASDAQ

Keep an eye on Greenwich LifeSciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Greenwich LifeSciences's (GLSI) price per share?

The current price per share for Greenwich LifeSciences (GLSI) is $14.5. The stock has seen a price change of $1.13 recently, indicating a 8.45% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Greenwich LifeSciences (GLSI)?

For Greenwich LifeSciences (GLSI), the 52-week high is $21.44, which is 47.86% from the current price. The 52-week low is $7.58, the current price is 91.29% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Greenwich LifeSciences (GLSI) a growth stock?

Greenwich LifeSciences (GLSI) has shown an average price growth of 0.41% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Greenwich LifeSciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Greenwich LifeSciences (GLSI) stock price performance year to date (YTD)?

As of the latest data, Greenwich LifeSciences (GLSI) has a year-to-date price change of 34.26%. Over the past month, the stock has experienced a price change of 2.26%. Over the last three months, the change has been -2.62%. Over the past six months, the figure is 5.45%.

help

Is Greenwich LifeSciences (GLSI) a profitable company?

Greenwich LifeSciences (GLSI) has a net income of -$8.89M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$9.33M. Furthermore, the EBITDA is -$10.53M.

help

What is the market capitalization of Greenwich LifeSciences (GLSI)?

Greenwich LifeSciences (GLSI) has a market capitalization of $190.6M. The average daily trading volume is 30.17K, indicating the stock's liquidity and investor engagement.